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In developed countries, most of hepatitis E human cases are of zoonotic origin. Swine is a major hepatitis E virus
(HEV) reservoir and foodborne transmissions after pork product consumption have been described. The risk for
HEV-containing pig livers at slaughter time is related to the age at infection and to the virus shedding duration.
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is a virus that impairs the immune response; it is highly
prevalent in pig production areas and suspected to influence HEV infection dynamics. The impact of PRRSV on
the features of HEV infections was studied through an experimental HEV/PRRSV co-infection of specific-pathogen-free
(SPF) pigs. The follow-up of the co-infected animals showed that HEV shedding was delayed by a factor of 1.9 in
co-infected pigs compared to HEV-only infected pigs and specific immune response was delayed by a factor
of 1.6. HEV shedding was significantly increased with co-infection and dramatically extended (48.6 versus 9.7 days for
HEV only). The long-term HEV shedding was significantly correlated with the delayed humoral response in co-infected
pigs. Direct transmission rate was estimated to be 4.7 times higher in case of co-infection than in HEV only infected
pigs (0.70 and 0.15 per day respectively). HEV infection susceptibility was increased by a factor of 3.3, showing the major
impact of PRRSV infection on HEV dynamics. Finally, HEV/PRRSV co-infection – frequently observed in pig herds – may
lead to chronic HEV infection which may dramatically increase the risk of pig livers containing HEV at slaughter time.Introduction
Hepatitis E virus is a non-enveloped single-stranded RNA
virus causing an acute hepatitis in humans. It is mainly
transmitted by the oro-fecal route and is responsible for
clinical signs similar to hepatitis A virus infection [1].
Chronic cases have been described, mainly in immuno-
compromised patients [2,3]. Four HEV genotypes have
been described. Genotypes 1 and 2 infect only humans
and circulate in Asia, Africa and Central America in epi-
demic waves linked to the consumption of contaminated
water [4–6]. Genotypes 3 and 4 are shared between
humans and other animal species and are responsible for
autochthonous sporadic cases in industrialized countries.
In particular, the number of hepatitis E cases linked to
genotype 3 has considerably increased in the last decade* Correspondence: nicolas.rose@anses.fr
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unless otherwise stated.[6,7], in relation to better diagnosis. This genotype is
highly prevalent in the swine population [8]. Some studies
have shown that swine and human HEV strains are genet-
ically very close [9] and HEV cross-species transmission
has been proven [10,11]. Moreover, a number of autoch-
thonous cases have been related to the consumption of
undercooked pork meat, especially liver products [12–16].
Thus, hepatitis E is now recognized as a foodborne zoo-
nosis for which domestic pigs are considered as the main
reservoir in developed countries [7,17,18]. Understanding
factors influencing the transmission dynamics of HEV in
pig herds is crucial to limit the risk of an introduction of
contaminated products in the food chain. Several studies
have described experimental HEV infection trials via oral
or intravenous route [19–24] but few studies were aimed
at quantifying HEV transmission [20,25]. The results of
these studies on HEV transmission were different than
those observed in pig farms on the field, with the latent
and infectious period estimates being generally longerThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ability of HEV infection dynamics is observed on pig
farms and has not yet been fully explained [29]. Some fac-
tors affecting swine immune response may also influence
the course of HEV infection. Porcine Respiratory and
Reproductive Syndrome Virus (PRRSV) is a highly preva-
lent virus that impairs the immune response. It has
been detected together with HEV in several studies but
no evidence of a causal relationship has been shown to
date [30–32]. Since chronic cases in humans are generally
linked to immunosuppressive conditions [33–36], PRRSV
might be suspected as a frequent co-factor affecting the
features of HEV infection in pigs.
The impact of a PRRSV infection on HEV infection dy-
namics (in terms of viral shedding duration and quantity,
transmission and humoral immune response) has there-
fore been studied through a transmission experiment
involving HEV/PRRSV co-infection of specific-pathogen-
free (SPF) pigs compared to an infection trial with HEV




A transmission trial with HEV only has been carried out
before the co-infection experiment [25]. The experiment
was conducted in Anses air-filtered level-3 biosecurity facil-
ities. Briefly, sixty-eight SPF Large-White piglets were used
for the experiment. Eight pigs were kept as negative con-
trols and the others were allocated to six rooms containing
two pens per room. Rooms 1 to 3 were used to evaluate
direct and environmental transmission, whereas Rooms 4
to 6 were used to examine between-pen transmission. The
inoculated pigs received orally 108 ge (genome equivalent)
under a volume of 10 mL of a genotype 3 HEV suspension
(strain FR-SHEV3e, Genbank access number JQ953665).
Individual fecal samples were collected four days before in-
oculation and three times per week from 0 to 39 days post-
infection (dpi) when the pigs were killed for necropsy.
Blood samples were collected twice a week during the same
period and clinical signs and rectal temperature were moni-
tored on a daily basis.
HEV/PPRSV co-infection experiment
Animal housing conditions and inoculation
The experiment was conducted in the same Anses air-
filtered level-3 biosecurity facilities. Twenty five-week-old
SPF Large-White piglets were included in the study; they
were HEV and PRRSV free and they did not have any ma-
ternal antibodies against these two viruses. Pigs were housed
in metallic flat decks with a punched floor for feces and
urine evacuation. As in the field situation, fecal material
could accumulate in the corners and was not removed dur-
ing the trial. Three rooms were used: two negative controlpigs were housed in Room 1 whereas the 18 remaining
piglets were randomly allocated to 3 independent pens
distributed in Room 2 and Room 3 (6 piglets per pen)
stratifying on gender (3 males and 3 females per pen),
weight and the litter they came from. Room 2 contained 2
pens separated by a solid partition to prevent contamin-
ation of a pen by the other one (Figure 1). The average
weights at weaning (sd) were 9.5 kg (2.7), 9.3 kg (1.6),
9.3 kg (2.3) and 9.3 kg (1.4) for Controls and groups #1, #2
and #3 respectively. In each pen, 3 piglets were inoculated
with both HEV and PRRSV at day 0. For inoculation, piglets
to be inoculated were grouped in a pen and they were put in
contact with their corresponding pen-mates at day 1. The 3
inoculated piglets received the following: (i) orally 108 ge
under a volume of 10 mL of a genotype 3 HEV suspension
(strain FR-SHEV3e, Genbank access number JQ953665)
prepared according to the protocol previously described
in Andraud et al. [25] (ii) and by nasal route 2.5 mL per
nostril of a PRRSV suspension (strain PRRS-2005-29-24-1
“Finistere”, genotype 1, subtype 1) titrating 105 TCID50/mL.
The experiment was performed in accordance with EU and
French regulations on animal welfare in experiments. The
protocol was approved by the Anses/ENVA/UPEC ethical
committee (agreement #16 with the National committee
for Ethics in animal experimentation).
Data collection
Individual fecal samples were collected three days before
inoculation and three times a week until the end of the ex-
periment (49 dpi). Blood samples were collected before in-
oculation and once a week until the end of the experiment.
Clinical examination was also performed (clinical signs,
rectal temperature, feces consistence, weight, food con-
sumption and trough cleanliness were recorded daily). Eu-
thanasia was carried out by intravenous injection of 1 g/
50 kg live weight of Nesdonal® (thiopental-sodium, Merial,
Lyon, France) followed by exsanguination. Necropsy was
performed and liver samples were taken.
Because HEV is a zoonotic agent, strict biosecurity mea-
sures were applied to prevent any transmission from pigs
to animal technicians.
Virology and serology analyses
HEV RNA quantification in fecal and liver samples was
performed, after manual total RNA extraction, using real-
time quantitative RT-PCR as described in Barnaud et al.
[37] and Andraud et al. [25]. The results were expressed
in terms of Cycle threshold (Ct). Standard quantification
curves were produced by plotting the Ct values against
the logarithm of the input copy numbers of standard
RNA. Standard RNA was obtained after in vitro transcrip-
tion of a plasmid pCDNA 3.1 ORF 2–3 HEV, as described
in Barnaud et al. [37]. The results are expressed in gen-
omic copy number per gram of feces (ge/g).
Figure 1 Experimental design of the co-infection experiment. Inoculated and susceptible contact animals are represented by black triangles
and white diamonds, respectively. Rooms 2 and 3 contained three pens housing three HEV/PRRSV co-inoculated (black triangles) and three susceptible
contact pigs (white diamonds). One negative control group was housed in Room 1.
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formed using the HEV ELISA 4.0v kit (MP Diagnos-
tics, Illkirch, France) according to the manufacturer’s
instructions, except the serum quantity used (10 μL
instead of 20 μL). This sandwich ELISA allows the
detection of all antibody classes (IgG, IgM and IgA)
and uses a recombinant antigen that is present in all
HEV strains. Samples were positive when the optical
density at 450 nm wavelength obtained for the sample
was higher than the threshold defined as the mean
for negative controls + 0.3.
PRRSV RNA detection in sera was performed using a
real-time RT-PCR as described in Charpin et al. [38].
Briefly, RNA extraction was performed using the NucleoS-
pin® 8 virus kit (Macherey-Nagel, Düren, Germany) accord-
ing to the manufacturer’s instructions. RNA detection was
then performed using the mix GoTaq 1-Step RT-qPCR Sys-
tem (Promega) supplemented with probes and specific
primers of the target gene (ORF7 pan-PRRSV) and of the
internal reference gene (swine Beta-Actin). The RT-PCR
was performed on a Bio-Rad Chromo4 real-time PCR de-
tection system (Bio-Rad) according to the following pro-
gram: 50 °C for 30 min, 94 °C for 2 min followed by
45 cycles of 94 °C for 15 s and 60 °C for 30 s. The results
are expressed in Ct.
Models
Estimation of durations related to HEV infection dynamics
The latent and infectious period durations and the dur-
ation of the period required to produce anti-HEV anti-
bodies were estimated using survival data analyses. For
each inoculated animal, the latent period was deter-
mined as the time elapsed between the inoculation day
and the date of the first positive fecal sample for HEV
RNA. The latent period after inoculation was fitted to a
gamma distribution, from which the shape and scale pa-
rameters were estimated by the maximum log-likelihoodmethod. A nonparametric bootstrap procedure was used
to determine the 95% confidence interval of the param-
eter estimates.
A parametric model for survival data was built to
estimate the duration of the infectious period, using the
RT-PCR performed on livers after euthanasia as the last
observation date. Two parametric models were tested
(log-normal and Weibull distributions of survival times)
and compared using the Akaike Information Criterion
(AIC).
The impact of PRRSV co-infection on the time to
HEV seroconversion was also studied with a parametric
survival model applied to the data from the co-infection
trial and the only HEV infection experiment [25]. The
link between the earliness of the HEV antibody response
and the duration of the infectious period was studied
with a Cox model. The immune response was considered
as absent or late if the delay before seroconversion was
longer than 25 dpi, and as early if it was shorter than 25
dpi [39].
All analyses were performed using the R software (surv-
reg and coxph functions) [40].
Quantification of HEV shedding, environmental
accumulation and transmission
The distributions of HEV shed viral loads with time (with
and without co-infection) are represented with box plot
series. A linear mixed model (proc Mixed, SAS 9.3, [41])
which took into account repeated measurements with
time was built to study the difference in the quantity
of HEV shed particles between co-infected and non
co-infected pigs.
The environmental load corresponds to the accumula-
tion of viral particles in the environment through fecal
shedding by infected animals, which is partially com-
pensated by the clearance rate hereafter denoted δ. The
clearance rate takes into account feces elimination
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tality in the environment. As described in Andraud
et al. [25], for each pen (k) and every sampling time (ti),
the average quantity of genome equivalent shed in the
environment per gram of feces was calculated with:
Vk tið Þ ¼
X
j
V jk tið Þ=Nk
where Vk
j (ti) represents the quantity of virus shed per
gram of feces in pen k by pig j at time ti and Nk the total
number of animals in pen k. Thus the cumulated viral
load in the environment of pen k between two sampling
times ti and ti + 1 is given by the equation:
Eki ¼ Ek tiþ1ð Þ
¼ Ek tið Þ þ
Z Δt
0




Two HEV transmission routes were investigated in
this study: (i) transmission due to direct contact be-
tween infected and naïve pigs; (ii) indirect transmission
via an environmental reservoir of the virus in the pen.
A Bayesian model similar to the one described in
Andraud et al. [25] was used. Briefly, on each sampling
interval Di = [ti, ti + 1] of duration di, the probability for
a susceptible pig j housed in pen k to escape infection is
given by:






(k) represents the proportion of shedding pigs in
the time interval Di located in pen k, Eki
(w) is the environ-
mental pool of viral particles in time interval Di in the
pen, βw is the within-pen transmission rate by direct
contact and βE
(w) is the within-pen environmental trans-
mission rate. For each pig j, the time interval in which
the infection occurred was determined by estimating the
latent period λj. Let DIj ¼ tIj ; tIjþ1
 
denote the time
interval during which the first positive fecal sample was
detected in pig j. The contribution of contact animal j
in pen k to the likelihood model, i.e. the probability
for its first positive fecal sample to stand in the inter-
val DIj ¼ tIj ; tIjþ1
 
is:
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The probability of infection (given by the first term of
the equation aforementioned) is weighted by the prob-
ability that the estimated latent period λj is consistent
with the data observed in inoculated animals. fLat repre-
sents the prior distribution of the latent period based onthe estimation of the latent period in inoculated animals.
The global likelihood is given by:





L jð Þ DI ;πw;Ejβw; β wð ÞE ; λ; δ
 
;
where Nc is the total number of contact pigs.
The direct and indirect transmission rates βw and βE
(w) re-
spectively, the latent period λj for each contact animal and
the HEV clearance rate were estimated by Bayesian infer-
ence using Monte Carlov Markov Chain. An informative
prior distribution based on Andraud et al. [25] was used
for the environmental clearance rate δ, which was assumed
to be normally distributed with mean 0.3 and standard de-
viation 0.075. The prior distributions of transmission pa-
rameters were based on the results obtained by Andraud
et al. [25]; they were constructed such that the expected
value is equal to the posterior mean and 33% of the prior
mass covers the 95% confidence interval for parameters
derived from data obtained by Andraud et al. [25,42] (nor-
mal distribution (−2,3) and (−13.5,5) for βw and βE
(w) re-
spectively). The prior distribution of the latent period in
contact pigs was based on the distribution of the latent
period in inoculated pigs (gamma distribution Γ(26,2)).
Parameter updating was performed sequentially by the
Metropolis-Hastings algorithm. Three chains were run with
random initial conditions, 110 000 steps per chain, a burnin
of 10 000 steps and thinning parameter of 10. Convergence
was assessed by visual inspection and diagnostic tests (auto-
correlation, Heidelberger, Gelman-Rubin diagnostics).
The whole model was performed using the R software [40].
Results
HEV-only infection experiment
In this trial, the average HEV latent period in inoculated
animals lasted 6.9 days (5.8; 7.9) and average infectious
period lasted 9.7 days (8.2; 11.2) (Table 1) [25]. Direct trans-
mission rate was estimated at 0.15 (0.03; 0.31) pigs per day
and indirect transmission rate was estimated at 2·10−6 g/ge/
day (1·10−7; 7·10−6) (Table 1) [25]. HEV serology results on
individual blood samples for HEV-only infected pigs are
presented in Additional file 1 [25].
HEV shedding and seroconversion in the context of
HEV/PRRSV co-infection
HEV infection data are presented in Figures 2 and 3 for
quantitative RT-PCR on fecal samples and serological re-
sults respectively. In our trial, all inoculated animals were
infected by HEV. None of the 2 negative-control pigs ex-
creted HEV from day 3 to day 49. Inoculated and contact
animals started to shed HEV between 9 and 18 dpi and be-
tween 25 and 32 dpi respectively. All exposed individuals
shed HEV until the end of the trial (49 dpi) (Figure 2). At
Table 1 Summary of the infectious dynamics parameters
and comparison with data from the HEV-only infection
experiment [25]
HEV + PRRSV HEV alone [25]
Latent period (days) 13.4 7.1
(8.6; 17.1) (3.2; 12.3)
Infectious period (days) 48.6 9.7
(27.9; 84.6) (8.2; 11.2)
Seroconversion period (days) 43.1 26.3
(35.7; 52.2) (23.5; 29.5)
Direct transmission (days−1) βw 0.70 0.15
(1.2.10−3; 3.67) (0.03; 0.31)
Indirect transmission (g/ge/d) βEw 6.6.10−6 2.0.10−6
(1.4.10−10; 1.3.10−4) (1.1.10−7; 7.0.10−6)
βw is the direct transmission rate, defined as the mean number of newly
infected pigs generated by a single infectious individual in a fully susceptible
population per day. βE
w represents the within-pen transmission rates related to
the environmental component, defined as the mean number of newly infected
pigs per HEV genome equivalent per gram of feces in the environment (see
text for more details). Numbers in brackets are the upper and lower limits of
the 95% credibility interval.
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negative livers being from contact pigs (Figure 2).
The detection of anti-HEV antibodies was performed on
all groups of animals until 49 dpi (Figure 3). None of the
negative controls showed anti-HEV antibody response.
Only 4 inoculated animals out of 9 produced anti-HEV
antibodies between 35 and 49 dpi, 3 in group 2 and one in
group 3; none of the inoculated animals from group 1 sero-
converted. Seven contact individuals out of 9 seroconverted
between 42 and 49 dpi, two from groups 1 and 2 and all
three contact animals from group 3 (Figure 3).Figure 2 HEV RNA quantification in fecal and liver samples from HEV
PCR results on individual fecal samples (HEV copies/g of feces) at each sam
correspond to periods in which infected individuals were considered in
positive fecal samples for each animal. dpi: day post infection; *testedPRRSV infection and seroconversion in the context of
HEV/PRRSV co-infection
All animals inoculated with PRRSV were viremic from
the first sampling time (7 dpi). The viremia of contact
animals started between 7 and 42 dpi. One contact indi-
vidual did not show any detectable PRRSV viremia dur-
ing the experiment (Figure 4). Finally, all animals except
2 contact individuals were viremic for PRRSV before
HEV shedding was detected.
Regarding clinical data (data not shown), inoculated and con-
tact animals showed hyperthermia (rectal temperature >40 °C)
between 1 and 14 dpi and 14 and 28 dpi, respectively. Co-
infected pigs necropsied at 49 dpi did not show any
macroscopic lesion possibly linked to hepatitis.
Quantification of HEV infection dynamics parameters in
the context of HEV/PRRSV co-infection
Convergence of MCMC was assessed through visual in-
spection and conventional diagnostic tests. Heidelberger
and Geweke diagnostics failed to reject the convergence
hypothesis, which was also supported by the Gelman-
Rubin test based on three independent chains with a
potential scale reduction factor (PSRF) close to 1.0 (≤1.02)
(Additional file 2).
HEV latent and infectious periods
The duration of the latent period in pigs inoculated with
HEV and PRRSV was fitted to a gamma distribution with
shape parameter α = 25.7 (11.6; 180.4) and scale parameter
s = 0.5 (0.08; 1.1) leading to an estimated mean duration of
the latent period of 12.9 days (12.8; 14.4). In contact ani-
mals, individual distributions of latent periods (Additional/PRRSV co-infected animals and contact pigs. Quantitative HEV RT-
pling time and from liver samples at necropsy. Shaded zones
fectious, corresponding to the time between the first and last HEV
in duplicate; abs: missing.
Figure 3 HEV serology results on individual sera samples from
HEV/PRRSV co-infected animals and contact pigs. Optical density
(450 nm) values of ELISA test HEV 0.4v per animal at different days post
infection. For each group, inoculated animals are indicated in black
(n= 3), contact pigs in light grey (n= 3) and negative control in dark
grey (n = 2). The cut off value is indicated by a dashed grey line.
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latent period, leading to a mean latent period duration of
13.4 days (8.6; 17.1) (Table 1).
The duration of the infectious period was fitted to a log-
normal distribution, leading to an estimated mean duration
of the infectious period of 48.6 days (27.9; 84.6) (Table 1).
Estimation of time to HEV seroconversion
Time-to HEV seroconversion was fitted to log-normal dis-
tribution, with means 43.1 days (35.7; 52.2) with PRRSV
co-infection and 26.3 days (23.5; 29.5) with only HEV in-
fection (Table 1). The duration of the infectious period was
significantly associated with the earliness of the humoral
immune response. An absent or late immune response was
related to a lengthening of the infectious period duration
showed by a delay in time-to end of shedding (Hazard
Ratio HR = 0.35 (0.19; 0.64)) (Figure 5).HEV shedding and accumulation in the environment
The distribution of the HEV shed viral load with time
(with and without co-infection) is shown in Figure 6.
PRRSV infection was found to be significantly associated
with the increase of the quantity of HEV particles shed
by inoculated animals (P = 0.05) from the linear mixed
model accounting for repeated measurements. The inter-
action between time and PRRSV infection was also signifi-
cant and positive, i.e. the impact of the PRRSV infection
increased with time (P = 0.04). However, the effect of the
PRRSV infection was not found to be statistically signifi-
cant in contact animals (P > 0.05).
The viral load accumulated in the environment was
modeled for each experimental pen (Figure 7). The en-
vironment was HEV-free until 15 to 20 dpi; then the en-
vironmental load increased and reached 1.0.108 to
1.5·108 ge/g of feces until the end of the trial.
HEV transmission parameters
The results show that, in experimental conditions, one
infectious pig was able to infect 0.70 pig per day by direct
contact (βw = 0.70 (1.18·10
−3; 3.67)) (Table 1). The indirect
transmission rate can be considered as the average number
of animals that can be infected by a single genome equiva-
lent present in the pen environment (βE
(w) = 6.59·10−6 g/ge/
day (1.43·10−10; 1.27·10−4)). In other words, the inverse of
βE
(w) corresponds to the average number of viral copy num-
ber of genome per gram of feces in the environmental pool
required to infect one animal in one day, i.e. 1.51·105 ge/g/
day (7.86·103; 7.00·109) (Table 1).
Discussion
Several studies suggested a possible link between HEV
and PRRSV infections [30–32]. Our study was aimed at
evaluating the impact of PRRSV infection on hepatitis E
dynamics of infection through an experimental HEV/
PRRSV co-infection trial. As shown in Table 1, the com-
parison of the results with those derived from a previous
infection trial with HEV alone [25] evidenced a modifi-
cation of hepatitis E infection dynamics in the presence
of PRRSV. Although the two trials were not carried out
simultaneously, they were conducted under the same ex-
perimental conditions making the comparison of the re-
sults fully relevant (same experimental facilities, same
handlers, pigs from the same SPF herd and genetically
similar, same age of the animals, same sex ratio, same
HEV strain, same dose, same inoculation protocol and
same contact structure).
HEV shedding was delayed in case of PRRSV co-infection,
with a latent period estimated to 13.4 days, against 7.1 days
with HEV alone [25], i.e. an increase by a factor of 1.9.
In the Bouwknegt et al. trial, the latent period was
estimated at only 3 days in intravenously inoculated ani-
mals [20], confirming that the route of inoculation
Figure 4 PRRSV RT-PCR results on individual blood samples. Shaded zones correspond to periods in which individuals were considered
viremic. The results are expressed in terms of Ct. dpi: day post infection; nt: not tested; N/A: not amplified; Ct: cycle threshold.
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with PRRSV co-infection: 48.6 days, against 9.7 days with
HEV alone, i.e. an increase by a factor of 5 (p < 0.01).
These results were therefore closer to estimates obtained
from field data (27 days (20; 39)) than experimental results
obtained with HEV only [26]). In the trial described by
Bouwknegt et al., the infectious period was estimated be-
tween 13 and 49 days according to replications, showing a
high inter-individual variability [20]. Moreover, the origin
of the animals included in this study and their status re-
garding PRRSV were not mentioned.
HEV shedding in inoculated individuals was also signifi-
cantly increased with PRRSV/HEV co-infection. However,
the effect of PRRSV infection on the quantity of shed viral
particles was not significant in contact animals. This couldFigure 5 Survival curves of time-to end of HEV shedding
according to early or late HEV seroconversion. The black and red
survival curves correspond to the duration of the infectious period
in pigs having an early seroconversion (less than 25 dpi) or a late
or absent seroconversion (more than 25 dpi) respectively.be explained by the low number of animals included – es-
pecially since one contact animals was lately infected by
PRRSV and another did not show any PRRSV viremia dur-
ing the experiment – and by a large inter-individual vari-
ability in contact animals. As a consequence of the longer
shedding period and the higher quantity of viral particles
shed in feces of co-infected animals, the viral load accumu-
lated in the environment was higher with PRRSV co-
infection with more than 108 HEV ge/g of feces estimated
in the environment, which causes a higher and longer
infection pressure on susceptible animals. The direct trans-
mission rate when animals were co-infected was increased
by a factor of 4.7 (0.70 versus 0.15 per day with HEV infec-
tion only [25]). Thus the direct transmission route played a
more important role in HEV transmission when animalsFigure 6 Distribution of the number of HEV genome equivalent
(log ge/g feces) shed by individual pigs with time in inoculated
animals with or without PRRSV co-infection. Co-infected animals
are indicated in green (n = 9), only-HEV infected animals [25] are in
black (n = 18).
Figure 7 Estimation of HEV environmental accumulation with PRRSV/HEV co-infection. Evolution of the estimated HEV genome load (ge/g)
in the environment of each pig group of the PRRSV/HEV co-infection experiment.
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amount of HEV particles shed individually than in HEV in-
fected pigs only. The indirect transmission rate was 3.3
times higher with co-infection (6.6·10−6 and 2.0·10−6 g/ge/
day respectively [25]). Otherwise stated, 3.3 times less viral
particles were required to infect a co-infected animal
(1.5·105 versus 5.0·105 ge/g for HEV only infected piglets
[25]). Because inoculated and contact animals (except two
contact pigs) were infected by PRRSV before HEV shed-
ding, these data suggest a higher HEV susceptibility in
PRRSV co-infected pigs. In a model built from an experi-
mental HEV infection by intravenous route, Bouwknegt
et al. showed that the HEV oral dose for which the infec-
tion probability was equal to 50% would be 1.4·106 ge/g
[22], which was 10 times more than the dose required to
infect a PRRSV co-infected pig in our study. These data
are consistent with the hypothesis of a higher HEV infec-
tion susceptibility in PRRSV co-infected pigs.
The time-to HEV seroconversion was 1.6 times longer
in PRRSV co-infected pigs than in HEV only infected
pigs (43.1 and 26.3 days respectively [25]). This impaired
immune response was significantly associated with a
lengthening of the infectious period duration and could
thus explain the presence of viral particles in livers when
pigs were euthanized more than 49 days post infection
for the inoculated ones. However, this study did not aim at
investigating the mechanisms leading to a possible immune
failure linked to PRRSV infection and the mechanisms
causing a chronic HEV infection. In humans, immuno-
pathogenic mechanisms leading to chronic hepatitis E are
poorly known. The role of cellular immunity in chronic
hepatitis E control has been shown [3,35,36]. A study was
led on patients suffering from HIV and chronically infected
with HEV [34]. One of them had a low anti-HEV lympho-
cyte T CD4+ rate, a persistent viremia (longer than
24 months) and a delayed anti-HEV seroconversion. Thus,
though immune mechanisms still need to be clarified,literature data suggest that an impaired innate and
adaptive immune response could lead to chronic HEV
infection in humans. In pigs, the immunopathogenic
mechanisms linked to PRRSV infection are not fully
understood yet, but PRRSV infection clearly results in
a late adaptive immune response [43,44]. Thus the
delayed anti-HEV seroconversion and the lengthening
of the infectious period duration that we observed in
PRRSV co-infected pigs seem consistent with the
immunopathogenic mechanisms of chronic hepatitis E
that have been described in humans (impaired cellular
and humoral immune response) and could be ex-
plained by a specific orientation of the immune re-
sponse linked to PRRSV infection. The increase of
the duration of the latent period might be explained
by the activation of the innate immune response
linked to the PRRSV infection, delaying HEV shed-
ding but this would require further work to assess
the underlying mechanisms.
To our knowledge, this work is the first study focusing
on the impact of HEV/PRRSV co-infection on hepatitis
E epidemiology in pigs. These results show that PRRSV
has a major impact on HEV infection dynamics and that
HEV/PRRSV co-infection could lead to extended HEV
shedding and maybe chronic infection. This chronicity
may dramatically increase the risk of pig livers contain-
ing HEV at slaughter age. Immunopathogenic mecha-
nisms leading to a chronic HEV infection have to be
further investigated. This study shows an important
interaction between an animal health concern - PRRSV,
which dramatically affects the competitiveness of pig
farms, and a zoonotic pathogen - HEV, which has a
major impact in human health. These data emphasize
the necessity to manage human and animal health
globally and the importance of PRRSV eradication pro-
grams, which could be a major lever in the control of
hepatitis E.
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Additional file 1: HEV serology results on individual sera samples
for only-HEV infected pigs [25]. Optical density (450 nm) values of
ELISA test HEV 0.4v per animal at different day post infection. Shaded
zones correspond to the period in which individuals were considered
HEV seropositive. dpi: days post infection, abs: missing.
Additional file 2: Estimation of transmission parameters by
Bayesian inference (MCMC estimation, 3 chains, 110 000 iterations,
10 000 burnin iterations, thinning interval = 10). βw is the direct
transmission rate, defined as the mean number of newly infected
pigs generated by a single infectious individual in a fully susceptible
population per day. βEw represents the within-pen transmission rates
related to the environmental component, defined as the mean number
of newly infected pigs per viral particle per gram of feces in the
environment. δ is the HEV clearance rate, taking into account feces
elimination through the metallic flat deck and HEV destruction in the
environment. λ1 to λ9 are latent periods for contact animals (see text
for more details).
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